Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA

World News: . []

Mechelen Belgium 24 LINK  2014 Galapagos NV Euronext GLPG a LINK  stage biotech company LINK  on developing novel mode of action medicines LINK  that recruitment of rheumatoid arthritis RA patients for the LINK  2 stud y with ...

More news and information about Galapagos NV

Published By:

Thomson Reuters: 06:30 GMT Monday 24th November 2014

Published: .

Search for other references to "galapagos" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us